Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Drug or technology

ABBV-1758

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 14, 2026 · PHASE 1/2 TRIAL

A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

ClinicalTrials.gov

This is a Phase 1/2 trial registration with no reported results; it describes a planned safety and dose-escalation study in a small population with surrogate endpoints (amyloid imaging) and safety assessments only.

PreliminaryABBV-1758 Placebo for ABBV-1758 Abbvie

Reported

Estimated enrollment210

Study sitesapproximately 55

Primary phasePhase 1, Phase 2

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support